At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 305 enrolled

Drug / intervention

Neladenoson bialanate (BAY1067197) +5 moredrug

Likely dose

Neladenoson bialanate (BAY1067197) 5 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03098979

NCT03098979Phase 2Completed

Compare CT.gov

A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double Blind, Dose-finding Phase II Trial to Study the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure and Preserved Ejection Fraction

Bayer·interventional·Posted Apr 4, 2017·Updated Jul 23, 2019

In Brief

A Phase 2 clinical trial evaluating Neladenoson bialanate (BAY1067197) and Placebo for Heart Failure. Completed, enrolled 305 participants across 76 sites in 12 countries.

Detailed Summary

The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY1067197) when given in addition to appropriate therapy for specific comorbidities.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsHeart Failure

CountriesAustria, Belgium, Bulgaria, Germany, Greece, Israel, Italy, Japan, Poland, Portugal, Spain, United States

Collaborators--

Timeline

Phase 2CompletedFinished

2017201820192020202120222023202420252026

First PostedApr 2017

Enrollment StartMay 2017

Primary CompletionMay 2018

Study CompletionJun 2018

TodayJul 2026

First PostedApr 4, 2017

Enrollment StartMay 10, 2017

Primary CompletionMay 23, 2018

Study CompletionJun 20, 2018

TodayJul 2, 2026

Enrollment to primary: 1.0 yearsPosted 9.2 years ago